Related Experiment Video
Updated: May 17, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Anti-HIV-1 nanotherapeutics: promises and challenges for the future
Supriya D Mahajan1, Ravikumar Aalinkeel, Wing-Cheung Law
1Department of Medicine, Division of Allergy, Immunology, and Rheumatology, State University of New York at Buffalo, Buffalo Niagara Medical Campus, Buffalo, NY, USA. smahajan@buffalo.edu
Abstract:
The advent of highly active antiretroviral therapy (HAART) has significantly improved the prognosis for human immunodeficiency virus (HIV)-infected patients, however the adverse side effects associated with prolonged HAART therapy use continue. Although systemic viral load can be undetectable, the virus remains sequestered in anatomically privileged sites within the body. Nanotechnology-based delivery systems are being developed to target the virus within different tissue compartments and are being evaluated for their safety and efficacy. The current review outlines the various nanomaterials that are becoming increasingly used in biomedical applications by virtue of their robustness, safety, multimodality, and multifunctionality. Nanotechnology can revolutionize the field of HIV medicine by not only improving diagnosis, but also by improving delivery of antiretrovirals to targeted regions in the body and by significantly enhancing the efficacy of the currently available antiretroviral medications.
More Related Videos
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Inhibitors of Viral Protein Synthesis
Human Virome
Retrovirus Life Cycles
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

